Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma

Talanta ◽  
2012 ◽  
Vol 93 ◽  
pp. 307-313 ◽  
Author(s):  
K. Mičová ◽  
D. Friedecký ◽  
E. Faber ◽  
T. Adam
Keyword(s):  
Mass Spectrometry ◽  
Tyrosine Kinase ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
Isotope Dilution ◽  
Kinase Inhibitors ◽  
Direct Injection ◽  
Spectrometry Method ◽  
Direct Injection Mass Spectrometry

Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma

2012 ◽  
Vol 413 (1-2) ◽  
pp. 143-149 ◽  
Author(s):  
Lutz Götze ◽  
Axel Hegele ◽  
Stephan Klaus Metzelder ◽  
Harald Renz ◽  
Wolfgang Andreas Nockher
Keyword(s):  
Tyrosine Kinase ◽  
Simultaneous Determination ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
Clinical Application ◽  
Kinase Inhibitors

Simultaneous identification and determination of eleven tyrosine kinase inhibitors by supercritical fluid chromatography-mass spectrometry

2019 ◽  
Vol 11 (16) ◽  
pp. 2211-2222
Author(s):  
Shaomin Zhang ◽  
Wei Jin ◽  
Yongjian Yang
Keyword(s):  
Mass Spectrometry ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Supercritical Fluid ◽  
Supercritical Fluid Chromatography ◽  
Analytical Method ◽  
Kinase Inhibitors ◽  
Chromatography Mass Spectrometry ◽  
Simultaneous Identification

A rapid analytical method using supercritical fluid chromatography (SFC) coupled to mass spectrometry for the simultaneous identification and determination of eleven tyrosine kinase inhibitors (TKIs) was developed and validated.

scholarly journals Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Marwa Fouad ◽  
Maxime Helvenstein ◽  
Bertrand Blankert
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Tyrosine Kinase ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
High Performance ◽  
Kinase Inhibitors ◽  
Therapeutic Window ◽  
Therapeutic Drug

Generally, tyrosine kinase inhibitors have narrow therapeutic window and large interpatient variability compared to intrapatient variability. In order to support its therapeutic drug monitoring, two fast and accurate methods were developed for the determination of recently FDA approved anticancer tyrosine kinase inhibitors, afatinib and ibrutinib, in human plasma using ultra high performance liquid chromatography coupled to PDA detection. Diclofenac sodium was used as internal standard. The chromatographic separation was achieved on an Acquity UPLC BEH C18 analytical column using a mobile phase combining ammonium formate buffer and acetonitrile at a constant flow rate of 0.4 mL/min using gradient elution mode. AµSPE (solid phase extraction) procedure, using Oasis MCXµElution plates, was processed and it gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach (β= 95% and acceptance limits = ±15%) over the ranges 5–250 ng/mL for afatinib and from 5 to 400 ng/mL for ibrutinib in human plasma.

Sign in / Sign up

Export Citation Format

Share Document